The Insight Room: Catching the Deadliest Cancer Earlier - Inside the PRECEDE–Azenta Partnership

Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find. In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone. Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape.